Data from the 4th Advanced Breast Cancer Meeting, Lisbon, which was held in Lisbon, Portugal, in 2017, recommended that anti-Her2 treatment should be changed only if brain metastasis is the only site of progression post anti-Her2 treatment, and no local treatment is available. This evidence concerns the gene ERBB2 and breast carcinoma.